FDA Approves Protagonist Therapeutics' MIMRYLO for Polycythemia Vera

Protagonist Therapeutics announced FDA approval for MIMRYLO (rusfertide) to treat erythrocytosis in adults with polycythemia vera. This milestone triggers $275 million in payments to Protagonist, comprising a $200 million opt-out fee and a $75 million approval milestone. The company is eligible for up to an additional $875 million in potential milestones and tiered royalties on global net sales.